<DOC>
	<DOCNO>NCT01683084</DOCNO>
	<brief_summary>The purpose study determine telmisartan effective slow progression abdominal aortic aneurysm reduce circulate concentration Abdominal Aortic Aneurysms ( AAA ) biomarkers .</brief_summary>
	<brief_title>Study Effectiveness Telmisartan Slowing Progression Abdominal Aortic Aneurysms</brief_title>
	<detailed_description>Currently , management option AAA surgical ( open endovascular ) base ongoing follow-up imaging regular interval . Telmisartan currently approve use United States Food Drug Administration management hypertension . If telmisartan find effective slow progression abdominal aortic aneurysm , would provide new treatment option patient AAA disease .</detailed_description>
	<mesh_term>Aneurysm</mesh_term>
	<mesh_term>Aortic Aneurysm</mesh_term>
	<mesh_term>Aortic Aneurysm , Abdominal</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<criteria>5085 year age able provide write informed consent AAA measure maximum diameter 3.54.9 cm CTA ultrasound Stable medication regime last six month No current indication AAA repair accord treat physician expectation revise within next year High likelihood compliance treatment 24 month Renal impairment ( i.e . creatinine &gt; 1.5x upper limit normal [ ULN ] ) Known significant renal stenosis ( &gt; 70 % ) one renal artery Chronic liver disease ( i.e . cirrhosis hepatitis ) abnormal liver function ( i.e . ALT 1.5xULN ) Electrolyte imbalance Active gout Current plan usage AT1 blocker ACE inhibitor Previous abdominal aortic surgery Currently pregnant intend become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Abdominal Aortic Aneurysm</keyword>
	<keyword>AAA</keyword>
	<keyword>telmisartan</keyword>
</DOC>